Latest news with #TMDX
Entrepreneur
4 days ago
- Business
- Entrepreneur
3 High-Growth Stocks Traders Love and Investors Should Watch
These three small stocks carry significant risk, but that volatility has served traders well this year; now it's time for long-term investors to take a look This story originally appeared on MarketBeat Swing traders and long-term investors rarely find common ground. However, in 2025, three small stocks have been making traders rich. They each carry significant risk, but that volatility has served traders well this year. Each of these stocks has significantly outperformed the broader market, even some Magnificent Seven names like NVIDIA (NASDAQ: NVDA). However, just because these companies aren't well known doesn't mean they're not good long-term investments. Each of these stocks has a long-term thesis that can be compelling to buy-and-hold investors. That is, if they have the risk tolerance for speculative stocks. Plus, these are established companies that haven't been on investors' radar. The immediate risks are that, if the economy improves, swing traders may look for other targets. Plus, the outlook for stocks could turn negative in the second half. Right now, that doesn't seem likely, so here are three stocks investors should use to take a page out of traders' playbooks. This Company's First-Mover Advantage Is a Lifesaver [content-module:Forecast|NASDAQ:TMDX] TransMedics Group Inc. (NASDAQ: TMDX) is a small mid-cap company with a market cap of around $4.42 billion as of this writing. The commercial-stage medical technology company has a first-mover advantage in organ transplant logistics. Its Organ Care System (OCS) has proven benefits over cold storage. TransMedics has the only FDA-approved device for transporting multiple organ types (e.g., heart, liver, lungs). That's a scalable advantage that traders and investors can seize on. Traders frequently target medical stocks like TransMedics because it has a limited float of approximately 30 million shares which makes it prone to sharp price swings. Plus, with short interest above 25%, the stock is closely watched by traders looking for short squeeze opportunities. TMDX stock is up 110% in 2025. However, even though it's above analysts' consensus price target, it's still comfortably below its 52-week high. The company has a premium valuation, but it's growing revenue and earnings year-over-year (YOY). This Stock is Going Nuclear as Demand for Energy Increases [content-module:Forecast|NYSE:SMR] The next on this list is NuScale Power Corp. (NYSE: SMR). The ticker symbol is also an abbreviation for small modular reactors. These are expected to be the future of nuclear power as the world continues to look for ways to meet the growing demand for power. In fact, the company's VOYGR power module is the only such module approved by the U.S. Nuclear Regulatory Commission. This demand comes from artificial intelligence (AI) applications. But the stigma around nuclear energy is changing as governments and corporations realize it's one of the few truly clean forms of energy available. SMR stock is up about 78% in 2025, with most of that growth coming since May. That's when the company announced contracts from the U.S. government, which will serve as a long-term source of revenue. Like TMDX, traders are attracted to SMR stock for its smaller float and 20% short interest. Short interest is down slightly since news of the Department of Energy (DoE) contracts dropped. However, momentum traders like the fact that the stock has over 70% institutional ownership to provide ample liquidity. An Up-and-Coming Fintech With a Clear Mission [content-module:Forecast|NASDAQ:DAVE] Dave Inc. (NASDAQ: DAVE) is a financial technology (fintech) company that offers a banking app to help level the playing field for everyday Americans struggling with high fees from traditional banks. The company offers a personal financial management tool, Budget; ExtraCash as a short-term liquidity alternative, a job application portal to promote supplemental or temporary work, and Dave Banking, a digital checking and demand deposit account. The company is in a competitive market, but it's managing to increase its total addressable market (TAM) every year. While Dave is not yet profitable, it is growing YOY revenue and is on a path to profitability. DAVE stock is up over 120% in 2025, with the strongest gains coming since May, but it has grown over 2,600% since it was a penny stock in 2023. Before you make your next trade, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list. They believe these five stocks are the five best companies for investors to buy now... See The Five Stocks Here
Associated Press
14-04-2025
- Business
- Associated Press
TMDX Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP Reminds TransMedics Group, Inc. (TMDX) Investors of Filing Deadline in Class Action Lawsuit
RADNOR, PA - April 14, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( ) informs investors that a securities class action lawsuit has been filed against TransMedics Group, Inc. ('TransMedics') ( NASDAQ: TMDX ) on behalf of those who purchased or otherwise acquired TransMedics securities between February 28, 2023, and January 10, 2025, inclusive (the 'Class Period'). The lead plaintiff deadline is April 15, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered TransMedics losses, you may CLICK HERE or copy and paste the following link into your browser: You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue; (2) TransMedics engaged in unsafe practices and hid safety issues and generally lacked safety oversight; and (3) the foregoing subjected TransMedics to heightened risk of scrutiny and regulatory risk. THE LEAD PLAINTIFF PROCESS: TransMedics investors may, no later than April 15, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages TransMedics investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit CONTACT: Kessler Topaz Meltzer & Check, LLP Jonathan Naji, Esq. (484) 270-1453 280 King of Prussia Road Radnor, PA 19087 [email protected] May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
Associated Press
12-04-2025
- Business
- Associated Press
TMDX Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds TransMedics Group, Inc. (TMDX) Investors of Filing Deadline in Class Action Lawsuit
RADNOR, PA - April 12, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( ) informs investors that a securities class action lawsuit has been filed against TransMedics Group, Inc. ('TransMedics') ( NASDAQ: TMDX ) on behalf of those who purchased or otherwise acquired TransMedics securities between February 28, 2023, and January 10, 2025, inclusive (the 'Class Period'). The lead plaintiff deadline is April 15, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered TransMedics losses, you may CLICK HERE or copy and paste the following link into your browser: You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue; (2) TransMedics engaged in unsafe practices and hid safety issues and generally lacked safety oversight; and (3) the foregoing subjected TransMedics to heightened risk of scrutiny and regulatory risk. THE LEAD PLAINTIFF PROCESS: TransMedics investors may, no later than April 15, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages TransMedics investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit CONTACT: Kessler Topaz Meltzer & Check, LLP Jonathan Naji, Esq. (484) 270-1453 280 King of Prussia Road Radnor, PA 19087 [email protected] May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. View the original release on
Associated Press
08-04-2025
- Business
- Associated Press
TMDX Deadline in 7 Days: Kessler Topaz Meltzer & Check, LLP Reminds TransMedics Group, Inc. (TMDX) Investors of Filing Deadline in Class Action Lawsuit
RADNOR, PA - April 8, 2025 ( NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that a securities class action lawsuit has been filed against TransMedics Group, Inc. ('TransMedics') ( NASDAQ: TMDX) on behalf of those who purchased or otherwise acquired TransMedics securities between February 28, 2023, and January 10, 2025, inclusive (the 'Class Period'). The lead plaintiff deadline is April 15, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue; (2) TransMedics engaged in unsafe practices and hid safety issues and generally lacked safety oversight; and (3) the foregoing subjected TransMedics to heightened risk of scrutiny and regulatory risk. THE LEAD PLAINTIFF PROCESS: TransMedics investors may, no later than April 15, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit Kessler Topaz Meltzer & Check, LLP Jonathan Naji, Esq. (484) 270-1453 280 King of Prussia Road Radnor, PA 19087
Bahrain News Gazette
03-04-2025
- Business
- Bahrain News Gazette
TMDX FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages TransMedics Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 15 Deadline in Securities Class Action Commenced by the Firm
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of TransMedics Group, Inc. (NASDAQ: TMDX) between February 28, 2023 and January 10, 2025, both dates inclusive (the 'Class Period'), of the important April 15, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased TransMedics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the TransMedics class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 15, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue; (2) TransMedics engaged in unsafe practices and hid safety issues and generally lacked safety oversight; (3) the foregoing subjected TransMedics to heightened risk of scrutiny and regulatory risk; and (4) as a result, defendants' statements about TransMedics' business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the TransMedics class action, go to call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: or on Twitter: or on Facebook: . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40 th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] GlobeNewswire Distribution ID 9416565
